Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- GenSpera, Inc.
- Registration Number
- NCT02876003
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- GenSpera, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02607553
- Locations
- 🇺🇸
University of Texas Health Science Center, Houston, Houston, Texas, United States
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- GenSpera, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT02381236
- Locations
- 🇺🇸
University of Texas Health Sciences Center, Houston, Texas, United States
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- GenSpera, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02067156
- Locations
- 🇺🇸
University of California, San Diego Moores Cancer Center, La Jolla, California, United States
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2016-08-23
- Lead Sponsor
- GenSpera, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01777594
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Oncology Consultants, PA, Houston, Texas, United States
🇺🇸University of Texas Health Sciences Center at Houston, Memorial Hermann Cancer Center, Houston, Texas, United States
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- GenSpera, Inc.
- Registration Number
- NCT01734681
- Locations
- 🇺🇸
The University of Texas Health Science Center, San Antonio, Texas, United States
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- GenSpera, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01056029
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University of Texas, Health Science Center,Cancer Therapy and Research Center, San Antonio, Texas, United States
🇺🇸University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States